Weekly Digest - May 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - May 2024
13 May 2024: Mabwell updates on clinical progress of 9MW2821 for Triple-Negative Breast Cancer
- Mabwell announced progress on the clinical study of 9MW2821, a Nectin-4-targeting ADC, for triple-negative breast cancer
- In a trial with 20 patients, 9MW2821 showed a 50% objective response rate (ORR) and 80% disease control rate (DCR), with one patient in complete response (CR) for 20 months
- The China NMPA accepted the investigational new drug application for 9MW2821 in combination with an immune checkpoint inhibitor
- 9MW2821 is also undergoing Phase III and Phase I/II studies for urothelial carcinoma, cervical cancer, and esophageal cancer, and has received Fast Track and Orphan Drug Designations from the U.S. FDA
